Skip to main content
Log in

Efficacy and Safety of Salmeterol/Fluticasone Propionate Combination Delivered by the Diskus™ or Pressurised Metered-Dose Inhaler in Children with Asthma

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and objective: Salmeterol and fluticasone propionate are well established in the treatment of childhood asthma, and their combination is effective in children aged 4–11 years. Asthma guidelines recommend that the inhaler device best suited to the individual should be used to administer asthma treatment. The aim of this study was to further evaluate the efficacy of salmeterol/ fluticasone propionate combination (SFC) delivered by the Diskus™ (50/l00μg, one inhalation twice daily) and compare it with that observed when SFC is delivered by a chlorofluorocarbon-free pressurised metered-dose inhaler (pMDI) [25/50μg, two inhalations twice daily] in children aged 4–11 years with persistent asthma.

Patients and methods: This equivalence study had a multicentre, randomised, double-blind, double-dummy, parallel-group design and comprised asthmatic children aged 4–11 years who required beclometasone (beclomethasone dipropionate) ≤500 μg/day (or equivalent). After a 2-week run-in using existing inhaled corticosteroid therapy, patients were randomised to receive SFC via Diskus™ (n = 213) or pMDI (n = 215, with 82% using a spacer) for 12 weeks. Salbutamol (Ventolin®) was provided for symptomatic relief. The primary endpoint was mean morning peak expiratory flow rate (PEF) recorded by patients during weeks 1–12. Secondary endpoints included other lung function parameters, day- and night-time symptoms, use of rescue medication and percentage of symptom- and salbutamol-free days. Adverse events and 12-hour overnight urinary cortisol concentrations were monitored to assess safety.

Results: Treatment with SFC, delivered by either device, was highly effective in improving patients’ morning PEF and asthma symptoms. Over the whole study period, morning PEF (mean ± standard error) improved by 37.7 ± 3.1 L/min in the Diskus™ group and by 38.6 ± 3.0 L/min in the pMDI group. The −0.9 L/min difference between groups (95% CI −7.1, 5.4) was within the predefined criterion for equivalence of (i.e. −15, 15 L/min). The median percentage of symptom-free and rescue medication-free days and nights increased considerably in both groups. For all efficacy parameters assessed, improvement occurred for all age groups as early as weeks 1–4, and was sustained over the 12 weeks. Both Diskus™ and pMDI treatments were well tolerated and their safety profiles were comparable.

Conclusion: SFC delivered via Diskus™ or pMDI was shown to be highly effective in asthmatic children aged 4–11 years. Children as young as 4 years were able to use the Diskus™ and pMDI effectively. The combination is clinically equivalent when administered via either device in this patient population. This means that both Diskus™ and pMDI (+ spacer) are suitable for administration of SFC, which provides prescribers/users with a choice of device.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Table II
Fig. 3
Table III

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. GINA. Global strategy for asthma management and prevention. Bethesda (MD): National Institutes of Health (National Heart, Lung, and Blood Institute); 2002. Publication No. 02-3659

  2. The International Study of Asthma and Allergies in Childhood. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC. Lancet 1998; 351: 1225–32

    Article  Google Scholar 

  3. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481–8

    PubMed  CAS  Google Scholar 

  4. Greening A, Ind P, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219–24

    Article  PubMed  CAS  Google Scholar 

  5. Condemi J, Goldstein S, Kalberg C, et al. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann Allergy Asthma Immunol 1999; 82: 383–9

    Article  PubMed  CAS  Google Scholar 

  6. Markham A, Jarvis B. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 2000; 60: 1207–33

    Article  PubMed  CAS  Google Scholar 

  7. Bateman E, Britton M, Carrillo J, et al. Salmeterol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma. Clin Drug Invest 1998; 16: 193–201

    Article  CAS  Google Scholar 

  8. Chapman K, Ringdal N, Backer V, et al. Salmeterol and fluticasone propionate (50/250μg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999; 6: 45–51

    PubMed  CAS  Google Scholar 

  9. Aubier M, Pieters W, Schlosser N, et al. Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93: 876–84

    Article  PubMed  CAS  Google Scholar 

  10. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 150: 1108–16

    Article  Google Scholar 

  11. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161: 527–34

    PubMed  CAS  Google Scholar 

  12. Ringdal N, Eliraz A, Pruzinec R, et al. The salmeterol/fluticasone combination is more effective than fluticasone propionate plus oral montelukast in asthma. Respir Med 2003; 97: 234–41

    Article  PubMed  CAS  Google Scholar 

  13. Jenkins L, Woolcock A, Saarelainen P, et al. Salmeterol/ fluticasone propionate combination therapy 50/250μg twice daily is more effective than budesonide 800μg twice daily in treating moderate to severe asthma. Respir Med 2000; 94: 715–23

    Article  PubMed  CAS  Google Scholar 

  14. NIH. Highlights of the expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health (National Heart, Lung, and Blood Institute); 1997. Publication No. 97-4051A. 1-50

  15. BTS. British guideline on the management of asthma. Thorax 2003; 58 Suppl. 1: 1–94

    Google Scholar 

  16. Busse W, Koenig S, Oppenheimer J, et al. Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. J Allergy Clin Immunol 2003; 111: 57–65

    Article  PubMed  CAS  Google Scholar 

  17. Chauhan S, Gogtay J. Aerosol delivery systems in childhood asthma. Indian J Pediatr 2001; 68 Suppl. 4: S17–22

    PubMed  Google Scholar 

  18. Nielsen K, Auk I, Bojsen K, et al. Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children. Eur Respir J 1998; 11: 350–4

    Article  PubMed  CAS  Google Scholar 

  19. Malton A, Sumby B, Dandiker Y. A comparison of in-vitro drug delivery from salbutamol Diskus and terbutaline Turbohaler inhalers. J Pharm Med 1996; 6: 35–48

    Google Scholar 

  20. Van den Berg N, Ossip M, Hederos C, et al. Salmeterol/ fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Pediatr Pulmonol 2000; 30: 97–105

    Article  Google Scholar 

  21. Jones B, Jarvis P, Lewis J, et al. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313: 36–9

    Article  PubMed  CAS  Google Scholar 

  22. Davies N, Feddah M, Brown K, et al. In vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorti-coid products: influence of inspiratory flow rates. J Pharm Pharm Sci 2000; 3: 318–24

    PubMed  Google Scholar 

  23. Newman S. Spacer devices for metered dose inhalers. Clin Pharmacokinet 2004; 43: 349–60

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Funding for this study was provided by GlaxoSmithKline Research & Development (UK).

The authors thank the following investigators who took part in this study: Dr U Putnik, Dr M Vasar (Estonia); Dr E Billard, Dr A Chace, Dr M Epstein, Dr A Jahiel, Dr M Lafourcade, Dr J Mathieu, Dr D Ortolan, Dr J Robert (France); Dr U Behre, Dr H Bresser, Dr F Drobnitzky, Dr F Friedrichs, Dr R Gall, Dr H Generlich, Dr W Kamin, Dr K Kirsten, Dr U Klettke, Dr K Krause, Dr P Soemantri, Dr A Von Berg (Germany); Dr V Adamovica, Dr I Budrevica, Dr I Cirule (Latvia); Dr R Emuzyte, Dr J Kudzyte (Lithuania); Dr H Brackel, Dr S Gans, Dr R Van Gent, Dr J Hoekx, Dr K Illy, Dr P Overberg, Dr W Van der Toom, Dr A Widdershoven (The Netherlands); Dr B Andersen, Dr D Bjaamer, Dr K Iversen, Dr O Moe, DrL Rolfsjord, Dr K Sivertsen (Norway); Prof. R Kurzawa, Dr T Malaczynska, Prof. J Pietrzyk, Dr A Slomka, Dr G Wykretowicz (Poland); Dr N Barroso, Dr A Escribano, Dr G Hernandez, Dr C Cordero (Spain); Dr M Ingemansson, Dr T Jakobsson, Dr K Oberg, Dr S Orjestad, Dr I Strannegard, Dr I Winnergard (Sweden); Dr M Clamp, Dr J Courtney, Dr A Darrah, Dr J Dunn, Dr C Fletcher, Dr B Glancy, Dr K Gruffyyd-Jones, Dr R Lal-Sarin, Dr I Swan (UK).

Drs Godwood and Balsara are employees of GlaxoSmithKline Reasearch & Development (UK); the other authors have no potential conflicts of interest that are directly relevant to the contents of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sima Balsara.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bracamonte, T., Schauer, U., Emeryk, A. et al. Efficacy and Safety of Salmeterol/Fluticasone Propionate Combination Delivered by the Diskus™ or Pressurised Metered-Dose Inhaler in Children with Asthma. Clin. Drug Investig. 25, 1–11 (2005). https://doi.org/10.2165/00044011-200525010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200525010-00001

Keywords

Navigation